エントリー企業詳細
Ecovia is a clean-tech startup, that specialises in compostable packaging solutions with its unique and revolutionary technology using clothing waste. This ground-breaking solution does not only solve plastic pollution but also ensures the best reuse of clothing waste that no one has done before. Ecovia can save our planet by putting an end to plastic pollution with its unique patented recipe.
As a company, Ecovia was founded in 2020 with a vision to make a cleaner environment. Ecovia provides a full range of compostable and eco-friendly packaging that is customizable as per customer needs.
We believe packaging should be part of a circular economy where the materials created must safely return to nature. Our packaging decomposes into healthy compost, leaving the same nutrients that organic waste leaves behind.
The startup’s R&D team is continuously working towards bringing more Earth Saving products. Ecovia intends to make the global fashion industry completely sustainable.
Nominated by
Plastic pollution is one of the biggest environmental pollution problems all over the world, and developing and using biodegradable packaging is a common trend in the world. In such a situation, Eco Via Ltd. has a unique technology using clothing waste. Currently, Bangladesh is the second largest RMG (Ready Made Garment) exporting country, so there are easy accesses to wastes or scraps of clothes, and this fact is making it reasonable to do this Eco Via’s business in Bangladesh.
Furthermore, exports of RMG from Bangladesh to Japan have increased by more than 40% year-on-year in FY2022-23, and the potential for collaboration with Japanese sewing manufacturers, trading companies, and apparel brands is expected to be greater in the future.
Eco Via is actively working for further collaboration with Japanese apparel brands and trading companies.
InsureCow is a pioneering agri-insuretech company with a mission to transform the dairy value chain. Our innovative suite of services empowers smallholder farmers, revolutionizing their practices through asset security, financial inclusion, farm management, and health tracking solutions. We bridge the gap between farmers, insurance companies, and lending institutions by leveraging advanced technologies, promoting transparency, and mitigating risks.
Our innovation lies in cattle identification through muzzle printometry, aiding farmers in health tracking and cost optimization. Insurance companies benefit from accurate cattle data, while financial institutions use it for informed lending. Our platform allows individual investors to support farms directly, yielding better returns than conventional deposits. This symbiotic model supports farmers and generates profits for investors.
Our comprehensive approach not only enhances farmers’ livelihoods but also creates a more resilient and efficient dairy industry. We’ve established a proven track record in reducing false claims, streamlining customer onboarding, optimizing claims processes, and enabling informed lending decisions.
Through strategic collaborations and partnerships, we extend our impact beyond individual farms, fostering sustainable growth in rural economies and contributing to environmental sustainability. InsureCow’s vision is rooted in innovation, social impact, and industry transformation, making us a key player in reshaping the future of agriculture and insurance.
Nominated by
In Bangladesh, low productivity of dairy and livestock sector is a big problem in spite of growing demand of these products. For example, the amount of milk produced per cow is only a quarter of that of neighboring country India. One of the reasons is the financial vulnerability of small scale dairy and livestock farmers. The business of InsureCow has potential to change this situation with a combination of insurance and health tracking technology. Not only InsureCow is the No.1 startup company in this sector in Bangladesh, but also their AI-powerd cattle identification and health tracking technology is the only one technology in the world. And, the model in which individual investor can invest in small holder farmer’s livestock is unique and interesting.
They have experience of expanding their business in developed countries such as European countries, so there is possibility to expand their business to Japanese Market.
Also, InsureCow has experience of becoming the champion of a renowned award in Bangladesh.
Dai3mimi is a technology developed for the elderly market in Japan, which has one of the highest aged populations globally. It uses patented acoustic technology, a material conduction system made of combined metal and plastic materials, to transmit sound waves directly into the inner ear through the skull. This bypasses the outer ear, eardrum, and middle ear, which are most susceptible to infection, damage, and degeneration. This patented technology provides clearer sound reception and effortless hearing for hearing-impaired and elderly users.
Dai3mimi also features a unique Rhythm Vibration Mechanism that combines sound and vibration technology to enhance its products for those suffering from tinnitus and dementia. This mechanism targets the trigeminal nerve, a crucial sensory nerve transmitting information from the face and head to the brain. By stimulating this nerve, Dai3mimi can activate the brain’s neural plasticity to relieve tinnitus effects and provide multi-sensory cognitive function training to elderly individuals with dementia. This refers to the brain’s ability to change and adapt in response to stimuli and plays a vital role in learning and memory.
Dai3mimi is not just a hearing aid device; it is a complete solution for elderly care.
Nominated by
The company received an award from the Hong Kong government for "Dai3mimi," a solution wearable device that improves the language development disorder and impaired communication skills of children and dementia problems of the elderly caused by hearing impairment. Based on the above, the company's technology is novel and superior and is expected to contribute to the Health and Medical Strategy.
i2Cool, a technology-based start-up incubated by the CityU HK Tech 300 programme, aims to promote novel, energy-free, environmentally friendly passive radiative cooling paint (patented in Hong Kong) for energy-saving and decarbonisation to achieve net-zero buildings. The self-developed, high-performance paint features an edge in solar reflection and thermal emissions, resulting in a significant sub-ambient cooling effect, without the need for electricity or ozone-depleting refrigerants. We will collaborate with different parties and organisations in the building, energy and paint industries to effectively demonstrate and promote our paint products. We will offer continuous product and business upgrades to maintain our technical competence and business sustainability. The ultimate goal of i2Cool is to have a remarkable environmental and social impact, mitigate the energy shortage and climate change problems, and facilitate the overall sustainable development and economic growth of China, while achieving carbon neutrality.
Nominated by
The company won an award at the International Exhibition of Inventions Geneva, the world's largest international exhibition dedicated to inventions, which is held annually in Geneva.
The company's technology is novel and superior, and is expected to directly contribute to the "realization of carbon neutrality and implementation of GX".
Based on the team’s world-first open magnetic particle imaging technology, this project aims at SLNB, the sentinel lymph node biopsy for breast cancer, and carries out the research and industrialization of the world’s first human-oriented magnetic particle imaging MPI equipment and clinical technology.
Nominated by
Bai Shi, Ph.D., Kyushu University, Japan, former researcher of BSBU Tokyo R&D Headquarters of Hitachi Group, currently distinguished professor of "Xiang Yuan Scholar" of Shenyang University of Technology, doctoral supervisor, youth discipline leader, founder of Liaoning Jiayin Medical Technology Co., LTD., CTO of Liaoning Jiayu Technology Co., LTD, Director of Liaoning Magnetic Medical Detection and Treatment Professional Technology Innovation Center (Provincial Key Laboratory), Liaoning Province excellent scientific and technological workers, Shenyang City leading talents.
Cognitica AI is an Artificial Intelligence (AI) technology company that focuses on solving industrial safety problems using Al and related technologies. Cognitica AI’s mission is to help create a world of zero industrial accidents. In order to achieve this goal we develop technologies and build products that solve industrial safety problems.
Industrial machines are heavy and powerful but not intelligent, a combination that results in great losses, including the accidents they cause. With the advent of AI, we can finally transform this situation by giving industrial machines and spaces the ability to see, recognize, remember and make decisions to prevent accidents, saving lives and money.
Nominated by
PSG-STEP
Cognitica AI Private Limited is a leading provider of innovative Artificial Intelligence (AI) based industrial safety products and solutions. Cognitica AI is nominated for the company’s commitment to create safer working environments by preventing workplace injuries, saving human lives and enhancing productivity through development of advanced AI systems and technologies targeted at industrial shop-floor and warehouse settings.
InfyU Labs is an emerging company specializing in the non-destructive assessment of internal quality in
fresh fruits. Our innovative technology allows us to quickly and accurately determine the quality of fruits,
providing buyers with the trust and confidence they seek before procurement even begins and reduce perishable
wastages.
Our vision is to establish a quality-driven marketplace for fresh commodities, where transparency and food
safety are paramount. By ensuring end-to-end quality traceability, we create a platform that connects growers
and buyers based on the superior quality of the produce.
Nominated by
It is my pleasure to strongly recommend Redicine Medsol for AEA2023.
InfyU is one of the most promising start-ups in Gujarat, with great technology, especially in the agritech sector.
Ostic Pharma Pvt Ltd was incorporated by alumni of IIT Bombay (Dr. Vinay Saini and Dr. Kusum Saini). It is a Startup incubated with SINE (Society for Innovation & Entrepreneurship), IIT Bombay, Mumbai, Maharashtra. We are an FDA and CDSCO approved facility dedicated to promote both disruptive & incremental innovation for the betterment of society. Our premier goal is to develop & provide affordable technology and products that improve people’s health & well being with a special
focus on the needs of vulnerable populations. We are working on Rapid TB diagnsotics, Rapid antigen and CRISPR based Molecular Based Diagnostics of Covid-19, Real Time Screening and Monitoring of Child Malnutrition, Neglected Tropical Diseases, Sickle Cell of Anemia and other diagnostics.
So far, we have introduced 08 products into the market (Covid-19, HIV, HCV, HBV, Malaria, Dengue, Syphilis, Pregancy) and serving different Governent Hospitals in India across different states.
We have FDA approved scaling up facility where we manufacture 5000 tests per day. We are planning to expand the scaling up facility in Union Territory so that we can manufacture around 100,000 tests per day and can peneterate market in South East Asia, Middle East, South Africa, Latin America including Japan. Ostic donated 14,000 Rapid Covid Tests during pandemic and secured Startup award.
Nominated by
Sometime ago, we attended one of the functions organized by JETRO in Mumbai and defended interest on collaborations with Japanese organisations (Startups and Academic Organizations) to develop and commercialization of products in healthcare diagnostics. We are in touch with Ms. Bhatia for last one year.
The petrochemical industry emits significant CO2. Our mission is Reducing atmospheric CO2 and tackle the the climate crisis by producing eco-friendly bio-based chemicals through fermentation, using renewable biomass as feedstock.
We provide bio-chemicals from renewable biomass as an alternative to petrochemicals.
The market will reach $30 trillion and all chemical users will be customers. Our core technologies are smart cells and bio-production processes.
Nominated by
University of Tsukuba
BioPhenolics inc. is a biotech company focusing on synthetic biology to achieve mass production of bio-based chemicals. It stands out with capabilities in both research and development, as well as process development. The process of synthesizing aromatic compounds from raw materials produced by microbial culture and refining from biomass, rather than raw materials derived from petroleum, is their unique technology. Bio-based chemicals act as CCUS (Carbon Capture, Utilization, and Storage) making chemicals and reducing CO2 at the same time.
Biophenolics, Inc. contributes greatly to the realization of a sustainable society, and is a startup worthy of being recommended for AEA2023.
Yanekara develops a cutting edge bidirectional electric vehicle (EV) charger, called YaneBox, and cloud software that controls charging/discharging timing of thousands of EV. Our technology turns EV into energy storage which plays vital role to integrate renewable energy (RE) into the power grid. Our core technology is the original electronic circuit board and embedded software that allow us to connect EV to solar inverter. This unique architecture makes the charging box compact, 1/3 the size of conventional products, and cheap, 30% cheaper solar and storage system. By mean of YaneBox, EV owners can power EV by solar energy and gain very high disaster resilience. In addition, we provide energy management system (EMS) that lowers the electricity bill. YaneBox is prepared to be launched in both B2B and B2C market. Last year we conducted a PoC in Kitakyushu city, in which we’ve tested prototype of YaneBox and EMS. To commercialize the product, we need to quantitatively evaluate performance of EMS with EV in normal operation. We are planning to conduct a PoB project in Kashiwanoha Innovation Field in cooperation with NEDO, UTokyo and Kashiwa city.
Nominated by
Todai Kashiwa Venture Plaza, Kanto head office, SME support lapan
Yanekara have moved into the Todai Kashiwa Venture Plaza since 2021. They are developing a system to optimize the supply of renewable energy and steadily producing results. Yanekara's greatest strength lies in its development capabilities that enable comprehensive development from hardware to cloud software. And, in terms of price, Yanekara has an advantage over their competitors. Furthermore, they are working with high ambition and strong passion !!
Global warming is a major concern for all of us. Yanekara, that aims to build an energy-self-sufficient society, has great potential to become a innovative major company. I strongly believe that Yanekara will get a lot of attention not only domestically but also globally in the near future.
We are proud to offer a cutting-edge surgical robotic system designed specifically for orthopedic hospitals that perform fracture surgeries. Our system allows for accurate, safe, and easy fracture surgeries without radiation exposure or excessive manpower. Unlike conventional methods, such as manual reduction or checking fluoroscopic images while wearing lead aprons, our system allows for precise alignment of bone fragments within 2 degrees and 2 millimeters while providing real-time 3D images. This reduces radiation exposure by 90%, cuts surgery time by 50%, and requires fewer surgical personnel. With our innovative solution, you can provide the best care for your patients while optimizing your resources.
Nominated by
AIRS Inc. (AI Robot Surgery) is on a transformative journey towards digital surgery, seamlessly complementing conventional analog procedures that rely on the expertise of medical staff. Their pioneering approach aims to elevate patient safety and treatment outcomes, particularly in fracture surgeries, while providing an intuitive and precise surgical environment for medical professionals.
There are compelling reasons to endorse this exceptional team. With 15 proficient members, including 5 PhDs, 5 Masters, and 2 orthopedic specialists, they boast a well-organized and diverse talent pool. The team has also built a robust system and infrastructure for manufacturing, licensing, and conducting clinical trials of medical devices, solidified by GMP certification. Collaborative partnerships with major university hospitals further reinforce their clinical validation efforts.
Their commitment to intellectual property rights is evident through the filing of 30 patent applications, including 7 overseas patents. Government recognition of their technical excellence with the NET certification (New Excellence Technology) speaks volumes about their innovative contributions.
Furthermore, they have strategically positioned themselves for success by leveraging the projected growth of the surgical robot market, estimated to reach 18.1 billion USD by 2030. The team has also established a sustainable revenue model through the sale of disposable devices.
In conclusion, AIRS Inc. stands at the forefront of digital surgery, poised to revolutionize fracture surgeries through advanced technology, a skilled team, and a promising market outlook. Without a doubt, I strongly recommend this excellent team for AEA 2023.
Cellus Inc. is developing a tumor-associated macrophage based next-generation immuno-oncology drug that responds to the immune evasion of cancer.
Making our best efforts to develop innovative anti-cancer drugs with a first-in-class drug development platform based on TAM.
Development of tumor-associated macrophage based next-generation immuno-oncology drugs of cellus would be a novel therapeutic strategy including the discovery of druggable biomarkers, platform-based analysis, clinical trials, and drug approvals.
We established by Aug, 2020 in Seoul National University hospital spin-off. Our capital amount is 1.2M USD and series A fund raised 3.5M USD until now. We have got 10 Korean Gov’s R&D fund programs with total 2.2M USD has been supported.
Now, cellus has 5 pipeline found and developing, 2 of pipelines proceeding pre-clinical stage with Lead, and 3 of pipelines are HIT development or optimization.
Nominated by
Cellus was founded in August 2020 by CEO Seong Keun Kim (ph.D. of immunology at the college of medicine, catholic university of Korea) and CMO Sun-wook Cho (a professor of endocrinology at Seoul National University Hospital).
Kim is developer of antibody, and immuno-oncology drugs of cellus are to overcome the limitations of third-generation immuno-oncology drugs such as low patient response.
Tumor-associated macrophage is a key player in tumor microenvironment, and can down-regulate T cell activity as well as up-regulate tumor progression.
In addition, they have been also reported to be actively involved in the acquisition of drug resistance.
Cellus expects to overcome the limitations and resistance of existing anti-cancer drugs by discovering TAM-specific biomarkers and developing therapeutic drugs, as well as providing a new therapeutic strategy for rare cancers without treatments.
At the time of initial investment attraction in July 2021, It was valued for 27.4 billion won, a five-fold increase.
We use AI technology and zebrafish technology to provide new drug test data to pharmaceutical companies.
Zebrafish is one of the alternative animal testing methods, which significantly reduces cost and period by reducing unnecessary animal testing.
In particular, we reduce human error due to minute experiments through an automated test process and provide highly reliable test data.
In the case of the domestic market, we are collaborating with big pharmas and 50 venture pharmaceutical companies.
Nominated by
Administration, Kyungpook National University
Along with the market expansion of animal test for new drug development, Zefit Inc. captured good market niche to provide a valuable data to pharmaceutical companies to save money, time and to reduce human errors associated with animal testing using state-of-the-art technology, such as AI and Zebrafish. Zebrafish test data is usually used in the prior stage before animal testing to pre-filter candidate substances that would fail in the actual animal testing. They automated this zebrafish new drug test process using robotics and AI technology, reducing cost and period by more than 50%, and reducing human error significantly to increase data reliability. In addition, zebrafish usually administer drugs by dissolving them in water, but our automated process enables oral administration or intravenous injection, which was previously difficult for humans, and the market response is good. In Korea, we are cooperating with two Korean big pharmaceutical companies, Lotte Central Research Institute, and 50 venture pharmaceutical companies. They are currently in a point to scale up their operation to international markets including Japan.
Castomize is a pioneering advanced manufacturing startup using 4D-printing to positively impact multiple industries around the world.
Our first focus industry is medical devices, where we are are making healthcare more accessible, effective, and less invasive. Our first device, 4D-printed casts, are created using advanced fabrication techniques and customized blends of polymers to provide unprecedented comfort, convenience, and efficiency for patients, doctors, hospitals, and medical insurers.
Over 180 million patients experience fractures annually, a market worth around 6 billion USD. Castomize’s 4D-printed casts are the best contender to displace the century-old solutions of plaster and fibreglass casts, having been validated by six hospitals around APAC, and having a co-development agreement the National Healthcare Group to finalize our cast and create a device poised to take over as the new standard of fracture treatment.
Core to Castomize’s operations is the focus on sustainability and promotion of access to healthcare for everyone, everywhere. Castomize’s business model consists of re-manufacturing, where casts sold to hospitals are salvaged and converted into first-aid kits meant for fracture healing in earthquake disaster zones, as 56% of all injuries during earthquakes are fractures, and Japan would be a key customer due to the frequency of earthquakes.
Nominated by
シンガポール工科デザイン大学のスピンオフ企業であるCastomize Technologiesは、高度な製造技術を駆使して新しい医療機器を生み出している。
同社の4Dプリント整形外科用ギプスは、軽量で完全防水、通気性に優れているため、患者にとってより快適である。医療従事者にとっては、より簡単で正確な装着が可能で、装着に必要な道具や時間も少なくて済む。さらに、このギプスは使い捨ての道具が少なく、患者の治癒過程を通じて再成形が可能であるため、環境にとってより持続可能である。
Castomize Technologies はシンガポールの5つの病院で試験を実施し、好評を得ている。また、シンガポールのナショナル・ヘルスケア・グループと製品共同開発契約を締結している。
長期的には、 Castomize Technologies は4Dプリンティングの領域知識を活用し、パッケージング、高度製造、その他の医療機器などの産業によい影響を与えたいと考えている。
Castomize Technologies の技術及びソリューションは、日本の社会的課題の解決に非常に適しており、幅広い分野で日本企業と提携の可能性が高いと思われる。
#Affordable Precision Care for Aging Society
Growing aging population, and its concomitant chronic diseases, has become a global issue. CDC data shows chronic diseases are the leading causes of death and disability, accounting for 75% of total medical expenditure. Existing precision devices are too costly and complex to address this massive demand of aging society. AIM solution offers affordable and easy access to precision care utilizing widely available modalities for large scale deployment.
AIM products includes
-DeepPACS: Medical AI service platform.
-DeepXray: Precision diagnosis and prognosis monitoring of chronic bone diseases using plain X-ray
-DeepSono: Precision diagnosis and prognosis monitoring of chronic heart diseases using plain Ultrasound
AIM have complete certification roadmap to support our market expansion plan in Taiwan(2023), SEA(2024) and Japan(2025).
– TFDA: DeepPACS(approved), DeepXray(approved), DeepSono(2024/1Q)
– FDA: DeepXray(2023/Q4)
– PMDA: 2024/1H
– ISO13485(approved)
– QMS(approved)
AIM have many clinical collaborations with multiple medical centers with exciting results. We have presented in 2022 TOA (Taiwan Orthopaedic Association) anniversary meeting and submitted multiple papers. AIM’s patent portfolio covers key product technologies. Multiple patent applications have been filed in the USA and Taiwan with 2 cases granted in Taiwan and 3 cases publicly disclosed in the USA.
Nominated by
Epoch Foundation (Garage+ Incubator)
The founder of AIM is an alumnus of the University of Tokyo, and the founding team comprises experts in image processing technology and a doctor.
The product achieves an accuracy rate of over 95%, requiring no modifications to existing medical workflows, with results obtained within 30 seconds.
Additionally, the product has already received TFDA (Taiwan Food and Drug Administration) approval and is projected to receive approval from the FDA (U.S. Food and Drug Administration) by September.
AIM has already collaborated with 3 hospitals for academia-industry partnerships, with implementation preparations in progress. It is expected that AIM will sign with 25 medical institutions this year.
Huijia Health is AI smart care solution provider based on the core technlogy nFOPT® – Non-invasive Fiber Optic Physiological Monitoring Technology with no electromagnetic waves in sleep area. It is a high sensitivity and accuracy bio-sensor that can monitor and track continuously, such as: respiratory, heart rate, coughs, pulse, blood pressure, sleep quality and many other vital signs. Applications include smart film(mattress), cushions, clothes, driver monitoring system, and smart care system for taking care a lot of elderly and babies at home or in the centers.Our solution can help to fix 2 big issues coming along with an aging population and pandemic -Shortage of caregivers and insufficient care quality.
nFOPT® bio-sensor is only 2mm thin that you do not need to wear it and put it under the pillow or mattress. With high-sensitivity,100x higher resolution, it is easier AI integration that can collect more details of health data to develop medical software for multiple diseases. We are developing into AI digital biomarkers such as Arrhythmia, Atrial Fibrillation, cardiopulmonary failure, sleep apnea, dementia, Parkinson’s disease, etc. Now, an ongoing hospital trial for hospic will provide dignity in end-of-life care by a prediction respiratory failure giving families a chance to say goodbye.
Nominated by
Epoch Foundation (Garage+ Incubator)
Because of the caregiving needs of the founder's family members, Huijia Health developed the innovative global "non-invasive fiber-optic physiological monitoring technology" (nFOPT).
The products include innovative mattresses, assistive devices, intelligent driving solutions, and smart fences.
Their efforts have been recognized with the Top 100 Innovative Products Award, APICTA Gold Award, and R&D 100 Awards. Huijia's products are expected to bring value to an aging society.
MUU is a food biotechnology startup that uses precision fermentation technology and proprietary microbes to create milk and dairy products that offer the same taste, texture, and properties as cow’s dairy, but are made without using a single cow.
As global food security and sustainability challenges escalate, traditional dairy production is one of the major cause. Although plant-based dairy alternatives exist, their taste dfferences hinder broad adoption from consumers. To overcome this challenge, we use precision fermentation and proprietary microbes to create milk proteins, the keys for replicating the taste and texture of cow’s dairy. This way we can create milk and dairy products that mimic the taste and mouthfeel of traditional dairy, making it effortless for consumers to transition to more sustainable options. Our products also promote health attributes as they are free of hormones, antibiotics residue, cholesterol, and lactose.
We target ASEAN+3 countries, covering Southeast Asia and Japan, Korea, China. Our business model is selling products to B2B partners including dairy producers, F&B manufacturers, and cafes & restaurants. So far, we have over 15 companies across Asia request for product trials.
Nominated by
CVD Corp develops the animal-free dairy products or the Cow’s milk made without using a cow (under product brand MUU) by using the precision fermentation technology and proprietary microbes.The primary advantage of MUU’s milk is taste, texture, and function identically as cow’s dairy but healthier and greener as free of cholesterol, animal hormones, antibiotic residues, and lactose while contains the good protein. The solution fulfills the health awareness lifestyle and achieves the sustainable food production for future food. Their milk is ideal for drinking and applying to blend with tea, coffee, cereal, ice-cream, baking, or cheese making.
Their technology is promising and the team holds backgrounds in biotechnology development, startup management and marketing. They won awards from Thailand, Japan and international stages. They have established the entity in Singapore, secured investment from Japanese and international investors as well as explored the business opportunity to expand Japan and global markets.
The technology has a lot of opportunity to collaborate with the dairy producers, F&B manufactures, cafes & restaurants to create appealing dairy alternatives tailored to Japanese preferences.
Nabsolute tackles the critical challenge of diminished healthcare product efficacy caused by low bioavailability, solubility, and stability of active ingredients in cosmeceuticals, nutraceuticals and pharmaceuticals.
Nominated by
Nabsolute develops a nano-modified biopolymer for better drug delivery system (called, Hy-N technology). Their globally patented Hy-N technology provides superior encapsulation for the molecule of active ingredients, enhancing their efficacy, stability and solubility of cosmeceutical and pharmaceutical products. This is addressing challenges of side effect, low bioavailability and instability frequently encountered in healthcare products. This technology is applicable to a wide spectrum of products, ranging from Food, Cosmeceutical, Pharmaceutical (Cancer Therapy, Cell & Gene Therapy), Regenerative Medicine to mRNA Vaccine.
The superior of Hy-N technology is the self-assembling properties which can accelerate product discovery and eliminate the need for costly setup or specialized equipment. Hy-N shatters traditional boundaries of cost, complexity and quality in bioactive molecule delivery.
Nabsolute’s team is specialized in Biomedical, Polymer Science and Healthcare Business. The technology was presented and awarded from Japan and international stages.
Currently, this technology has undergone scientific testing and proven to be more effective, safer to use, and easier to synthesize. It is already incorporated in products of several reputable domestic and international companies. It is also piqued the interest of Japanese cosmeceutical brands. These create possibility to scale up into cosmeceutical and pharmaceutical market in Japan.
UniFAHS is a leader in phage biotechnology and applications in Southeast Asia. We have intellectual property for our production processes and materials, which gives us an advantage in the market.
We offer phage-based products to enhance food safety from farm to fork. and phage designation by customized approach service such as phage for AMR bacteria. Currently, we serve the products in animal and food sectors under brand PhagePromptTM
Vision
A pioneer in the application of phage technology, ensuring the sustainable production of safe
foods from farm to fork, promoting the holistic concept of one health, and actively combating
the global challenge of antimicrobial resistance.
Market Analysis
Antimicrobial Resistance, One health, Environment are indeed a global crisis, phage technology is the promising tool to solve this problem in various segments.
Marketing Plan
Partnership strategies which gives us a competitive advantage over competitors.
Bussiness model B2B (Product&Service).
Nominated by
Food manufacturers and livestock farms use various methods to sterilize food to prevent contamination and loss by bacteria and viruses. However, the chemical substances and antibiotics make a lot of problems to the environment and global food supply chain.
UniFAHS develops a phage-based solution for food, animal and human safety and sustainability. The phage-based solution is a natural bacteria killer used as a safe and natural antimicrobial agent as an alternative to chemicals and antibiotics. It can be applied to ensure food safety and prevent huge loss in the poultry farm, food and meat industries.
The team is specialized in the biotechnology, phage technology and application.
The technology responds to the global challenge of antimicrobial resistance and unsafe food supply chain which opens the opportunity to implement solution to promote the food safety and sustainability in Japan.
With the increase in global energy consumption, our Earth is getting hotter than ever. Global warming directly relates to the imbalance in the reflection/absorption of solar radiation. Our key product RARE, a radiative cooling paint, reflects 98% of total solar infrared and radiates 95% in the atmospheric transparent windows. Adhered well to a wide range of materials, including glass, plastic, wood, metal, or concrete, RARE cools down external surfaces absolutely to the ambient temperature. Composed of popular materials, RARE is produced at 1 ton per day and is simple to scale up depending on the market need. We are expanding rapidly in the northern part of Vietnam, and are looking forward to growing in larger markets, such as Japan.
Nominated by
Foreign Trade University
RARE, proudly nurtured within the cradle of Comit. This exceptional creation exudes not only the prowess to capture and embrace heat but, more profoundly, to radiate it with an unmatched intensity. Behold, a transcendent marvel that eclipses all prevailing anti-heating paints in the market, standing alone as the sole coating layer capable of maintaining ambient temperatures ceaselessly. With a bond that transcends surfaces and a dust-repelling allure, RARE's allure is irresistible. The startup's journey commenced at the very bedrock, forging core technology through meticulous craftsmanship of chemical compositions, precision in production parameters, and orchestrating the dance of heat flows for optimal performance. Emerging from the crucible of innovation, RARE has ascended to industrial proportions, poised to embellish vast domains. As the dawn of research and development unfolds, Comit's confidence emanates—a symphony of creation that shall orchestrate kindred innovations tailored to the tapestry of market demands.